- Basic Science · OxPhos Biology · Metabolic Oncology
Clinical Evidence in Pancreatic Cancer
Lixumistat is being evaluated in patients with advanced pancreatic cancer in combination with standard of care at MD Anderson Cancer Center. Early data show encouraging efficacy with a manageable safety profile.
Response Rate at RP2D (5/10 patients)
0
%
Disease Control Rate
0
%
N=25
Total Study Size
No DLTs
Dose-Limiting Toxicities Observed
Response Rate at RP2D (5/10 patients)
0
%
Disease Control Rate
0
%
N=25
Total Study Size
No DLTs
Dose-Limiting Toxicities Observed
- Basic Science · OxPhos Biology · Metabolic Oncology
Lixumistat in Advanced Pancreatic Cancer
Lixumistat in combination with gemcitabine and nab-paclitaxel (standard of care) in patients with advanced PDAC. Principal Investigator: Dr. Shubham Pant, MD Anderson Cancer Center. Registry: NCT05497778.
- Early Results
Encouraging Efficacy Signal at the Recommended Dose
Among the first 10 evaluable patients at RP2D, 5 showed clinical responses — 50% response rate. Disease control rate 80%. No dose-limiting toxicities. Safety and PK profile established across 100mg QOD to 1,200mg QD.
Data presented at ASCO GI (January 2025) and ESMO GI (July 2025). Interim publication in progress.
